(DRNA), Analyst Ratings, Price Targets, Predictions

The latest price target for (: DRNA) was reported by Chardan Capital on December 9, 2021. The analyst firm set a price target for $38.25 expecting DRNA to fall to within 12 months (a possible NaN% downside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for (: DRNA) was provided by Chardan Capital, and downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of , and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for was filed on December 9, 2021 so you should expect the next rating to be made available sometime around December 9, 2022.

While ratings are subjective and will change, the latest (DRNA) rating was a downgraded with a price target of $28.00 to $38.25. The current price (DRNA) is trading at is $undefined, which is out of the analyst’s predicted range.